The effect of TOR and IL-10 on the differentiation of monocyte-derived DC
| Treatment . | IL-4 + GM-CSF . | CD14 . | CD1a . | CD40 . | CD80 . | CD86 . | HLA-DR . |
|---|---|---|---|---|---|---|---|
| — | — | 150 ± 130 | 1.5 ± 0.4 | 13 ± 3.2 | 1.1 ± 0.1 | 21 ± 13 | 690 ± 410 |
| — | + | 2.6 ± 3.0 | 17 ± 12 | 180 ± 110 | 17 ± 10 | 10 ± 2.0 | 250 ± 180 |
| TOR 1 μmol/L | + | 1.2 ± 0.2 | 11 ± 6.9 | 140 ± 87 | 8.3 ± 1.6 | 9.0 ± 2.2 | 170 ± 87 |
| TOR 5 μmol/L | + | 1.3 ± 0.4 | 2.4 ± 1.2* | 87 ± 55* | 5.6 ± 4.0* | 26 ± 8.7† | 290 ± 160 |
| TOR 10 μmol/L | + | 2.9 ± 2.7 | 1.1 ± 0.1* | 69 ± 39* | 1.2 ± 1.2* | 190 ± 95* | 620 ± 440* |
| IL-10 | + | 74 ± 56* | 2.3 ± 1.6* | 33 ± 29* | 5.8 ± 3.2* | 6.8 ± 3.8 | 380 ± 220 |
| Treatment . | IL-4 + GM-CSF . | CD14 . | CD1a . | CD40 . | CD80 . | CD86 . | HLA-DR . |
|---|---|---|---|---|---|---|---|
| — | — | 150 ± 130 | 1.5 ± 0.4 | 13 ± 3.2 | 1.1 ± 0.1 | 21 ± 13 | 690 ± 410 |
| — | + | 2.6 ± 3.0 | 17 ± 12 | 180 ± 110 | 17 ± 10 | 10 ± 2.0 | 250 ± 180 |
| TOR 1 μmol/L | + | 1.2 ± 0.2 | 11 ± 6.9 | 140 ± 87 | 8.3 ± 1.6 | 9.0 ± 2.2 | 170 ± 87 |
| TOR 5 μmol/L | + | 1.3 ± 0.4 | 2.4 ± 1.2* | 87 ± 55* | 5.6 ± 4.0* | 26 ± 8.7† | 290 ± 160 |
| TOR 10 μmol/L | + | 2.9 ± 2.7 | 1.1 ± 0.1* | 69 ± 39* | 1.2 ± 1.2* | 190 ± 95* | 620 ± 440* |
| IL-10 | + | 74 ± 56* | 2.3 ± 1.6* | 33 ± 29* | 5.8 ± 3.2* | 6.8 ± 3.8 | 380 ± 220 |
Adherent PBMC were cultured with IL-4 (500 U/mL) + GM-CSF (50 ng/mL) in the presence or absence of toremifene (TOR) or IL-10 (100 U/mL). After 7 days in culture the cells were stained for various cell surface markers and analyzed with flow cytometry. The data represent MFIRs (see “Materials and methods”) of 5 individual experiments (mean ± SD).
P < .05 and
P < .01 comparing TOR and IL-4 + GM-CSF or IL-10 and IL-4 + GM-CSF versus IL-4 + GM-CSF.